|
| MS form | Sample size | Dosage and administration | Changes in EDSS | Adverse events | Results | Ref |
|
| SPMS | 10 | 1.6 × 106 cells/Kg
Intravenously | Initial 6.1
decrease after treatment | Macular rash, scalp pruritus, upper-respiratory tract infection, and urinary-tract infection | No changes in the posttreatment period for T cell subset counts (CD3, CD4, CD8, CD19, and CD56)
Decrease of T1 hypointense lesion volume after treatment
Increase in optic nerve area and reduction in visual evoked response latency | [97] |
|
| SPMS and PRMS | 25 (23/2) | 2.95 × 107 cells
Intrathecally | Initial 5.5 to 7
decrease or stability after treatment in 68% of patients | N/A | MRI score decrease in 68% of patients
Increase of IL-6 gene expression
No changes in IL-4, IL-6, IL-10, IFN-γ, and TGF-β gene expression | [98] |
|
| SPMS and RRMS | 10 (9/1) | (a) High 1 × 108 cells
(b) Medium 3.2–5.2 × 107 cells
(c) Low 1.1–1.5 × 106 cells
Intrathecally and intracisternally | Initial 4.0 to 7.5
decrease after treatment | Transient encephalopathy with seizures in one patient | Clinical but not radiological efficacy
Improvement in 5/6 and worsening in 1/6 patients
New or enlarging lesions in 5/7 and Gadolinium (Gd+) enhancing lesions in 3/7 patients | [99] |
|
| MS | 15 | 6.32 × 107 cells
Intrathecally | Initial 6.7
decrease after treatment | Transient fever and headache | Increase of CD4+CD25+ Treg
Decrease of CD40+, CD83+, CD86+, and HLA-DR on myeloid dendritic cells | [100] |
|
| MS | 1 | N/A | N/A | The patient development headache, nausea, vomiting, and difficulty of ambulation | Accumulation of CD-68 positive
myelin-laden macrophages and T cells
Extensive demyelination in a pattern typical of multiple sclerosis in brain biopsy | [101] |
|
